Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2002 Jan 7;195(1):125–133. doi: 10.1084/jem.20011097

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2002, The Rockefeller University Press

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 6. — Cross-presentation requirements beyond tumor cell uptake. (A) Antibody enhances cross-presentation only when coating the tumor antigen-expressing myeloma cell. arp (NY-Eso-1−ve) and cag (NY-Eso-1 +ve) cells were treated with anti–syndecan-1 or isotype control antibody and fed to HLA A2.1 +ve DCs, either alone, or together, at DC/tumor ratio of 1:1. Tumor cell–loaded DCs (after maturation with cytokine cocktail), were used to stimulate autologous T cells. After two stimulations, the number of peptide-specific T cells was quantified using peptide-pulsed DCs as APCs in an ELISPOT assay. (B) FcγR blocking antibodies decrease cross-presentation. DCs were pretreated with anti-FcγR blocking antibodies (CD16⁺CD32) or with isotype controls, before feeding tumor cells treated with anti-syndecan (mAb-Tum) or isotype (Iso-Tum) control antibody, as described in the legend to Fig. 3 A. Antigen-specific T cells were quantified after two stimulations, in an ELISPOT assay using peptide-pulsed DCs as APCs.

Figure 6. — Cross-presentation requirements beyond tumor cell uptake. (A) Antibody enhances cross-presentation only when coating the tumor antigen-expressing myeloma cell. arp (NY-Eso-1−ve) and cag (NY-Eso-1 +ve) cells were treated with anti–syndecan-1 or isotype control antibody and fed to HLA A2.1 +ve DCs, either alone, or together, at DC/tumor ratio of 1:1. Tumor cell–loaded DCs (after maturation with cytokine cocktail), were used to stimulate autologous T cells. After two stimulations, the number of peptide-specific T cells was quantified using peptide-pulsed DCs as APCs in an ELISPOT assay. (B) FcγR blocking antibodies decrease cross-presentation. DCs were pretreated with anti-FcγR blocking antibodies (CD16⁺CD32) or with isotype controls, before feeding tumor cells treated with anti-syndecan (mAb-Tum) or isotype (Iso-Tum) control antibody, as described in the legend to Fig. 3 A. Antigen-specific T cells were quantified after two stimulations, in an ELISPOT assay using peptide-pulsed DCs as APCs.

	
		OSZAR »